Imiquimod and lentigo maligna: A search for prognostic features in a clinicopathological study with long-term follow-up

British Journal of Dermatology

Volumn 160, Issue 5, 2009, Pages 994-998

  Powell, A M ^a   Robson, A M ^a   Russell Jones, R ^a   Barlow, R J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Imiquimod; Lentigo maligna; Melanoma in situ; Prognosis; Therapy

Indexed keywords

FUSIDATE SODIUM; FUSIDIC ACID; IMIQUIMOD;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CRYOTHERAPY; DISEASE COURSE; ERYTHEMA; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; LONG TERM CARE; MALE; MALIGNANT LENTIGO; MONOTHERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RETROSPECTIVE STUDY; SKIN BIOPSY; SKIN INFLAMMATION; SKIN IRRITATION; STAPHYLOCOCCUS INFECTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT FAILURE;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BIOPSY; FACIAL NEOPLASMS; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 64849088533     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09032.x     Document Type: Article

References (17)

1. Hutchinson J. Notes on the cancerous and new growths in general. Arch Surg (London) 1890 2 : 83 6.
2. Dubreuilh MW. Lentigo malin des vieillards. Ann Dermatol Syphiligr (Paris) 1894 3 : 1092 9.
3. Roberts DLL, Anstey AV, Barlow RJ et al. UK guidelines for the management of cutaneous melanomas. Br J Dermatol 2002 146 : 7 17.
4. Schon M, Bong AB, Drewnoik C et al. Tumor selective induction of apoptosis and the small molecule immune response modifier imiquimod. J Natl Cancer Inst 2003 95 : 1138 49.
5. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000 143 : 843 5.
6. Naylor MF, Crowson N, Kuwahara R et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003 149 (Suppl. 66 66 70.
7. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004 29 : 15 21.
8. Spenny ML, Walford J, Wernchniak AE et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007 79 : 149 52.
9. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol 2006 155 : 653 6.
10. Weinstock MS, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987 16 : 303 10.
11. Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer 1968 21 : 893 911.
12. NIH Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992 268 : 1314 19.
13. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators - progress toward treating inflammation, infection and cancer. Lancet Infect Dis 2001 i : 189 98.
14. Smith KJ, Hamza S, Skelton H. The imidazoquinolines and their place in the therapy of cutaneous disease. Expert Opin Pharmacother 2003 4 : 1105 19.
15. Fisher GH, Lang PG. Treatment of melanoma in situ on sun damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease. Arch Dermatol 2003 139 : 945 7.
16. van Meurs T, van Doorn R, Kirtschig G. Recurrence of lentigo maligna after initial complete response to treatment with 5% imiquimod cream. Dermatol Surg 2007 33 : 623 7.
17. Geisse J. Commentary on lentigo maligna recurrence. Dermatol Surg 2007 33 : 626.